Advice
following an abbreviated submission:
midodrine hydrochloride (Bramox®) is accepted for use within NHS Scotland.
Indication under review: in adults for the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate.
Midodrine hydrochloride (Bramox®) 5mg tablets have been shown to be bioequivalent to the unlicensed midodrine 5mg product currently in use in NHS Scotland. The availability of midodrine hydrochloride (Bramox®) will allow the prescribing of a licensed medicinal product, with a resultant small net budget impact, based on estimates from primary and secondary prescribing and expenditure data from 2013/14.
Download detailed advice110KB (PDF)
Medicine details
- Medicine name:
- midodrine hydrochloride (Bramox)
- SMC ID:
- 1094/15
- Indication:
- in adults for the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate.
- Pharmaceutical company
- Brancaster Pharma Limited
- BNF chapter
- Endocrine system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 October 2015